Kyle LaHucik

One of the nation’s premier cancer institutions is looking at a hefty second batch of capital to support future drugs in the field.

The Column Group's drug R&D team, known as TCG Labs Soleil, has been busy churning out new portfolio companies since it unveiled with a $400 million-plus fund ...

Eli Lilly is deepening its presence in the non-opioid pain field by buying California biotech SiteOne Therapeutics, which is in a similar arena as the recent landmark approval for Vertex's pain drug.

Juvenescence is out with a $76 million Series B-1, its first equity funding since before the Covid-19 pandemic.

A longevity startup called Retro Biosciences is working on personalized blood disorder therapies thanks to a partnership with the Murdoch Children's Research Institute in Australia. The California biotech, which has ...

Pfizer is dishing out $1.25 billion upfront and up to $4.8 billion in milestone payments to Shenyang-based 3SBio for the exclusive ex-China license to the biotech's PD-1xVEGF bispecific.

Apnimed's oral drug met the efficacy bar in the first of two Phase 3 studies in obstructive sleep apnea, the biotech said Monday morning. The biotech plans to report results ...

It's been 13 weeks since Aardvark Therapeutics' $94 million initial public offering on Feb. 13 in the bleakest streak for biotech IPOs since 2022.

Pathos AI, seeking to upend cancer drug development with artificial intelligence and large multimodal models, has raised the third-largest private funding round in biotech so far this year.

Galapagos is turning heads by reconsidering whether to do its planned spinoff, which was originally announced in January.